

Komedikation und Polypharmazie in der Psychiatrie: Geschichte, Hintergründe, Konzepte und gegenwärtige Anwendung

Hans-Jürgen Möller, München, Susanne Stübner, Augsburg, und Renate Grohmann, München

Literatur

- Adan-Manes J, Garcia-Parajua P. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. *J Clin Pharm Ther* 2009;34:245–6.
- Andreazza AC, Young LT. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. *Int J Neuropsychopharmacol* 2014;17:1039–52.
- Aparasu RR, Mort JR, Brandt H. Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. *Res Social Adm Pharm* 2005;1:446–59.
- Baghai TC, Marcuse A, Brosch M, Schule C, et al. The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. *World J Biol Psychiatry* 2006;7:82–90.
- Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. *CNS Drugs* 2011;25:383–99.
- Bauer M, Bschor T, Pfennig A, Whybrow PC, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. *World J Biol Psychiatry* 2007;8:67–104.
- Blier P. Rational site-directed pharmacotherapy for major depressive disorder. *Int J Neuropsychopharmacol* 2014;17:997–1008.
- Blier P, Ward HE, Tremblay P, Laberge L, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. *Am J Psychiatry* 2010;167:281–8.
- Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. *Schizophr Bull* 2002;28:75–84.
- Correll CU, Shaikh L, Gallego JA, Nachbar J, et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. *Schizophr Res* 2011;131:58–62.
- Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. *J Clin Psychiatry* 2007;68:935–40.
- Daniel DG, Randolph C, Jaskiw G, Handel S, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. *J Clin Psychopharmacol* 1994;14:340–3.
- de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. *Psychiatr Serv* 2004;55:491–3.
- Falkai P, Wobrock T, Lieberman J, Glenthøj B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. *World J Biol Psychiatry* 2005;6:132–91.
- Falkai P, Wobrock T, Lieberman J, Glenthøj B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: long-term treatment of schizophrenia. *World J Biol Psychiatry* 2006;7:5–40.
- Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. *Int J Neuropsychopharmacol* 2014;17:1083–93.
- Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. *Acta Psychiatr Scand* 2002;106:323–30.
- Frye MA, Ketter TA, Leverich GS, Huggins T, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. *J Clin Psychiatry* 2000;61:9–15.
- Gardos G. Antipsychotic polypharmacy or monotherapy? *Neuropsychopharmacol Hung* 2005;7:72–7.
- Gilmer TP, Dolder CR, Folsom DP, Mastin W, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. *Psychiatr Serv* 2007;58:1007–10.
- Glezer A, Byatt N, Cook R Jr, Rothschild AJ. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. *J Affect Disord* 2009;117:18–23.
- Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. *J Clin Psychiatry* 2006;67:1261–5.
- Goren JL, Parks JJ, Ghinassi FA, Milton CG, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. *Jt Comm J Qual Patient Saf* 2008;34:571–82.
- Grohmann R, Engel RR, Ruther E, Hippus H. The AMSP drug safety program: methods and global results. *Pharmacopsychiatry* 2004;37(Suppl 1):S4–11.
- Grohmann R, Hippus H, Helmchen H, Ruther E, et al. The AMUP study for drug surveillance in psychiatry – a summary of inpatient data. *Pharmacopsychiatry* 2004;37(Suppl 1):S16–26.
- Grohmann R, Ruther E, Schmidt LG. Unerwünschte Wirkungen von Psychopharmaka – Ergebnisse der AMUP-Studie. Berlin: Springer, 1994.
- Grunze H, Vieta E, Goodwin GM, Bowden C, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. *World J Biol Psychiatry* 2009;10:85–116.
- Grunze H, Vieta E, Goodwin GM, Bowden C, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2010 on the treatment of acute bipolar depression. *World J Biol Psychiatry* 2010;11:81–109.
- Grunze H, Vieta E, Goodwin GM, Bowden C, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorder. *World J Biol Psychiatry* 2013;14:154–219.
- Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. *Int J Clin Pharmacol Ther* 2007;45:643–53.

Prof. Dr. H.-J. Möller, Dr. Renate Grohmann, Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität, Nussbaumstraße 7, 80336 München, E-Mail: hans-juergen.moeller@med.uni-muenchen.de
Priv.-Doz. Dr. Susanne Stübner, Bezirkskrankenhaus Augsburg, Dr.-Mack-Straße 1, 86156 Augsburg

31. Heeringa M, Beurskens R, Schouten W, Verduijn MM. Elevated plasma levels of clozapine after concomitant use of fluvoxamine. *Pharm World Sci* 1999;21:243–4.
32. Henkel V, Seemüller F, Obermeier M, Adli M, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. *J Affect Disord* 2009;115:439–49.
33. Honer WG, Thornton AE, Chen EY, Chan RC, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. *N Engl J Med* 2006;354:472–82.
34. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. *Br J Psychiatry* 2005;187:243–7.
35. Janssen B, Weinmann S, Berger M, Gaebel W. Validation of polypharmacy process measures in inpatient schizophrenia care. *Schizophr Bull* 2004;30:1023–33.
36. Karagianis J, Novick D, Pecenek J, Haro JM, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17 000 patients. *Int J Clin Pract* 2009;63:1578–88.
37. Kotzan JA, Maclean R, Wade W, Martin BC, et al. Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort. *Clin Ther* 2002;24:237–48.
38. McIntyre RS, Jerrell JM. Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. *J Clin Psychiatry* 2009;70:240–6.
39. Millan MJ. On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. *Int J Neuropsychopharmacol* 2014;17:1009–37.
40. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. *Arch Gen Psychiatry* 2010;67:26–36.
41. Möller HJ. Is evidence sufficient for evidence-based medicine? *Eur Arch Psychiatry Clin Neurosci* 2009;259(Suppl 2):S167–72.
42. Möller HJ. Pharmacotherapy of schizophrenic patients: achievements, unsolved needs, future research necessities. *Curr Pharm Biotechnol* 2012;13:1476–89.
43. Möller HJ. Le nuove frontiere della psicofarmacologia: focus su antipsicotici e antidepressivi. In: Fiorillo A (editor). *Lezioni di Psichiatria per il nuovo Millennio*. Roma: Il Pensiero Scientifico Editore, 2010: 43–58.
44. Möller HJ, Maier W. Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. *Eur Arch Psychiatry Clin Neurosci* 2010;260:25–39.
45. Möller HJ, Riedel M, Müller N, Fischer W, et al. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. *Pharmacopsychiatry* 2004;37:270–8.
46. Möller HJ, Seemüller F, Schennach-Wolff R, Stübner S, et al. History, background, concepts and current use of comedication and polypharmacy in psychiatry. *Int J Neuropsychopharmacol* 2014;17:983–96.
47. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. *Am J Psychiatry* 2009;166:980–91.
48. Paris J. *The use and misuse of psychiatric drugs*. Oxford: Wiley-Blackwell, 2010.
49. Patrick V, Schleifer SJ, Nurenberg JR, Gill KJ. Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. *Psychiatr Serv* 2006;57:21–3.
50. Poeschla BD, Bartle P, Hansen KP. Serotonin syndrome associated with polypharmacy in the elderly. *Gen Hosp Psychiatry* 2011;33:301.e9–11.
51. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? *J Psychiatr Pract* 2007;13:97–105.
52. Sachs GS, Peters AT, Sylvia L, Grunze H. Polypharmacy and bipolar disorder: what's personalality got to do with it? *Int J Neuropsychopharmacol* 2014;17:1053–61.
53. Seemüller F, Riedel M, Obermeier M, Bauer M, et al. Outcomes of 1014 naturalistically treated inpatients with major depressive episode. *Eur Neuropsychopharmacol* 2010;20:346–55.
54. Seemüller F, Schennach-Wolff R, Obermeier M, Henkel V, et al. Does early improvement in major depression protect against treatment emergent suicidal ideation? *J Affect Disord* 2010;124:183–6.
55. Spina E, Avenoso A, Scordo MG, Ancione M, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. *J Clin Psychopharmacol* 2002;22:419–23.
56. Stahl SM. Antipsychotic polypharmacy. Part I: Therapeutic option or dirty little secret? *J Clin Psychiatry* 1999;60:425–6.
57. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. *Curr Med Chem* 2004;11:313–27.
58. Stübner S, Grohmann R, von Stralendorff I, Rütter E, et al. Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. *J Clin Psychiatry* 2010;71:1293–307.
59. Suzuki T, Uchida H, Watanabe K, Nakajima S, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. *Hum Psychopharmacol* 2008;23:455–63.
60. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr., et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophr Res* 2008;100:20–38.
61. Thompson A, Sullivan SA, Barley M, Strangé SO, et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial. *Psychol Med* 2008;38:705–15.
62. Valuck RJ, Morrato EH, Dodd S, Oderda G, et al. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. *Curr Med Res Opin* 2007;23:2567–76.
63. Wade AG, Crawford GM, Nemeroff CB, Schatzberg AF, et al. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. *Psychol Med* 2011;41:2089–97.
64. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. *Cochrane Database Syst Rev* 2002:CD002305.
65. Zhu B, Ascher-Svanum H, Faries DE, Correll CU, et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. *BMC Psychiatry* 2008;8:19.